In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography

Drug Discovery Today

Volumn 6, Issue 6, 2001, Pages 293-302

  Aboagye, Eric O ^a   Price, Patricia M ^a   Jones, Terry ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTINEOPLASTIC AGENT; CARBON 11; DAUNORUBICIN; DIPRENORPHINE; FLUCONAZOLE; FLUMAZENIL; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; LAZABEMIDE; LIPOCORTIN 5; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NEUROLEPTIC AGENT; OXYGEN 15; RACLOPRIDE; RADIOISOTOPE; SELEGILINE; TAMOXIFEN; TEMOZOLOMIDE; THYMIDINE; WATER;

DRUG DEVELOPMENT; DRUG METABOLISM; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; REVIEW;

EID: 0035282803     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(01)01684-1     Document Type: Review

References (48)

1. Bottlenecks in anticancer drug discovery and development: in vivo pharmacokinetic and pharmacodynamic issues and the potential role of PET
2. Radio-imaging in small animals
3. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture
4. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro
5. Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability
6. High-resolution PET studies in Alzheimer's disease
7. Local cerebral metabolic changes in acute ischemic strokes
8. Does fluorine-18 flurodeoxyglucose metabolic imaging of tumours benefit oncology?
9. Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
10. In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance
11. Studies on the metabolism of the novel antitumor agent [N-methyl-11C]N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials
12. From triazines and triazenes to temozolomide
13. 11C-methyl]methylisocyanate and application of microwave heating to labelling the novel anticancer agent Temozolomide
14. The kinetic behavior of temozolomide in man
15. The discovery and profile of fluconazole
16. 18F-labelled fluconazole in healthy human subjects by positron emission tomography
17. Fluorouracil: biochemistry and pharmacology
18. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in vivo imaging of drug action
19. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumor and normal tissues
20. Measurement of tumour and normal tissue perfusion (NT) by positron emission tomography (PET) in the evaluation of antivascular therapy: results in the phase I study of combretastatin A4 phosphate (CA4P)
21. Dopamine release from nigral transplants visualised in vivo in a Parkinsons's patient
22. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography
23. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography
24. 11C]1-chloro-2-iodoethane for radiolabelling ADEPT prodrugs
25. Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status
26. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma
27. Positron emission tomographic assessment of 'metabolic flare' to predict response of metastatic breast cancer to antiestrogen therapy
28. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
29. Antipsychotic drug doses and neuroleptic/dopamine receptors
30. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
31. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects
32. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride
33. 2 receptors by the neuroleptic ziprasidone (CP-88 059-01) determined by positron emission tomography
34. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by RO 19 6327
35. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis
36. 2-[C-11]thymidine imaging of malignant brain tumors
37. A general method to correct PET data for tissue metabolites using a dual-scan approach
38. 11C]thymidine PET imaging studies: validation studies
39. 11C] thymidine
40. Carbon-11-thymidine and FDG to measure therapy response
41. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography
42. Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas
43. Glucose uptake by gliomas after treatment
44. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation
45. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation
46. Non-invasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil
47. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group